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Escherichia coli are opportunistic pathogens with the potential to cause a variety of
infections in both humans and animals and in many cases have developed antimicrobial
resistance. In this study, we characterized extended-spectrum cephalosporin resistant
(ESCR) E. coli isolates from diseased companion animals (dogs, cats, and horses)
and related the results to clinical findings. ESCR E. coli clinical isolates obtained over
a 6-year period were screened for extended-spectrum β-lactamase (ESBL) and/or
plasmid mediated AmpC (pAmpC) and virulence markers likely to be associated with
extraintestinal pathogenic E. coli (ExPEC). ESBL and/or pAmpC genetic determinants
were identified in 79.9% of the ESCR E. coli isolates with blaCTX−M genes being the
most common ESBL genotype of which blaCTX−M−15, blaCTX−M−14, and blaCTX−M−55
were the most prevalent. In addition, blaCMY−2 was the most common genotype
identified amongst pAmpC producing isolates. Phylogenetic group typing showed that
B2 was the most prevalent phylogroup among the ESCR E. coli isolates, followed
by the closely related phylogroups D and F which are also associated with extra-
intestinal infections. ESCR was also identified in phylogroups commonly regarded as
commensals (B1, A, and C). Virulence factor (VF) scores >2 were mostly present
amongst isolates in phylogroup B2. Higher virulence scores were found in isolates
lacking ESBL/pAmpC resistance genes compared with those carrying both genes
(p < 0.05). Five of phylogroup B2 isolates, were typed to the pandemic virulent
O25b-ST131 clone and three ST131 isolates carrying blaCTX−M−15 belonged to the
subclade C2/H30Rx whilst one isolate carrying blaCTX−M−27 typed to the recently
described sub-clade C1-M27. MLST typing also identified other sequence types
commonly associated with infections in humans (ST410, ST10, and ST648). Most ESCR
E. coli isolates obtained in pure growth were cultured from normally sterile body sites
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(mostly from urinary tract infections, UTIs) whilst only a small proportion were obtained
from body sites populated with commensal flora (p < 0.0001). Our study has shown
that ExPEC ESBL/pAmpC producing E. coli isolates are common amongst companion
animal isolates and are associated with colonization and infection. In addition, their
isolation from a normally sterile site is likely to be clinically significant and warrants
antimicrobial treatment.
Keywords: ESBL, Escherichia coli, virulence, antimicrobial resistance, companion animals, United Kingdom
INTRODUCTION
Escherichia coli are Gram-negative bacteria belonging to the
Enterobacteriaceae family, which are ubiquitous colonizers of
the gastro-intestinal (GI) tract in humans and companion
animals. The Enterobacteriaceae, most notably E. coli and
Klebsiella pneumoniae, are among the most important agents
of serious hospital acquired and community-onset bacterial
infections in humans and resistance to antimicrobial agents
in these bacteria has become an increasingly serious problem
(Paterson, 2006). Over the last two decades, extended-spectrum
β-lactamase (ESBL)-producing E. coli have been isolated with
increasing frequency from human and animal samples (Coque
et al., 2008; Dolejska et al., 2013). ESBLs confer resistance
to extended-spectrum cephalosporins (ESCs, e.g., ceftiofur,
cefpodoxime, ceftazidime, ceftriaxone) and monobactams, and
often express resistance to non-β-lactam antimicrobials leaving
only limited therapeutic options (Pitout and Laupland, 2008). In
addition, isolates carrying plasmid-mediated cephalosporinases
(pAmpC) have a broader spectrum of resistance, including the
cephamycins and are not inhibited by β-lactamase inhibitors,
resulting in resistance to almost all therapeutically available
β-lactam agents (Pitout, 2012). E. coli is commonly identified
from clinical infections in companion animals, including
urinary, respiratory, skin and soft tissues, GI tract, joint
and wound infections (Guardabassi et al., 2004; Zogg et al.,
2018). In veterinary medicine, the β-lactam agents are arguably
the most important and widely used antimicrobial class for
treating bacterial infections. Recent United Kingdom data
shows that β-lactam agents are prescribed in 43.6% of
canine and 70.8% of feline antimicrobial agent prescriptions
(Singleton et al., 2017). Their widespread usage may be due
to their safety, antimicrobial spectrum, availability of orally
bioavailable formulations, favorable pharmacokinetic properties
for treating commonly encountered infections and the low
cost of many products. First generation cephalosporins and
amoxicillin + clavulanic acid are among the most commonly
prescribed drugs for dogs (Murphy et al., 2012), whilst penicillin
(with or without an aminoglycoside) is commonly prescribed
for horses (Hughes et al., 2013). Worryingly, recent data has
shown that cefovecin, a third generation cephalosporin, has
become the most frequently prescribed antimicrobial agent in the
United Kingdom for cats (Singleton et al., 2017).
Similar to the epidemiology of ESBL associated infections in
people, the CTX-M type ESBLs (CTX-M-1, -14, and -15) are
common amongst companion animal isolates and SHV-12 and
TEM-52 have also been reported (Ewers et al., 2012). In addition,
there seems to be a match in the geographic distribution
of the human and animal CTX-M enzymes, with CTX-M-1
predominating in Africa and Europe, CTX-M-14 in Asia and
North America and CTX-M-15 β-lactamase in North America,
Europe, and Africa (Rubin and Pitout, 2014).
The occurrence of ESBL/AmpC producing E. coli has been
reported in both healthy and diseased companion animals
(Gandolfi-Decristophoris et al., 2013; Bogaerts et al., 2015),
with some reports indicating high fecal carriage rates amongst
healthy animals (Maddox et al., 2012; Baede et al., 2015).
However, the clinical significance of these isolates and their
involvement in animal disease occurring as either opportunistic
pathogens or simple colonizers, has been very rarely investigated.
Additionally, the lack of clinical and laboratory guidelines for
the management of ESBL/pAmpC-producing animal infections,
leads to important dilemmas for veterinary microbiologists
in deciding when is appropriate to provide susceptibility
results to support antimicrobial therapy for these infections.
Additional clinical or laboratory information, which could
support the distinction between colonization and true infection
associated with ESBL/AmpC producing Enterobacteriaceae is
critical in order to avoid unnecessary use of antimicrobials in
companion animals.
Thus, this study aimed to characterize ESBL/pAmpC
producing E. coli isolates from diseased companion animals
(including dogs, cats and horses), with a focus on relating their
genetic background to clinical and paraclinical findings in order
to determine the role they play in companion animal infections.
MATERIALS AND METHODS
Bacterial Isolates
Escherichia coli isolates were obtained from companion animal
clinical specimens submitted to the Microbiology Diagnostic
Laboratory, Liverpool Institute of Veterinary Science between
January 2010 and August 2016. Clinical specimens, mainly
originated from animals admitted to the University of Liverpool
Small Animal and Equine Referral Hospitals, included urine
samples collected by cystocentesis, body fluids, tissue biopsy
samples, bile and/or liver biopsy, swabs from skin infections
and otitis externa cases, fecal samples from diarrheic patients
or animals suspected of GI disease. These were plated out
aerobically on culture media following site-specific culture
protocols, including 5% sheep blood agar (Oxoid, Basingstoke,
United Kingdom) and were incubated at 37◦C for 1–7 days.
Clinical isolates presumptively identified as E. coli based on a
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positive reaction on Eosin Methylene Blue Agar (EMBA; Oxoid,
Basingstoke, United Kingdom) and which showed reduced
susceptibility to cefpodoxime (10 µg) and/or cefoxitin, were
selected for this study. Species identification of clinical isolates
was performed using API 20E identification kits (Biomerieux,
France) and also by PCR detection of the uidA gene for
confirmation of E. coli (McDaniels et al., 1996). Bacterial culture
data, including specimen site, the type of bacterial growth
obtained (pure or mixed, repeat E. coli isolation from the
same case) and the number of bacterial species isolated from
each specimen were recorded in the Veterinary Diagnostic
Laboratory database.
Phenotypic Testing for ESBL/pAmpC
Production
Cefpodoxime was used as a marker for extended-spectrum
cephalosporin resistance (ESCR) and for ESBL screening. All
cefpodoxime-resistant E. coli isolates were tested for ESBL
production by combination disc testing (CDT) using third
generation cephalosporins alone (cefpodoxime, ceftazidime,
and cefotaxime) and in combination with clavulanic-acid
(MAST Group, United Kingdom) on Mueller-Hinton Agar
(Oxoid, Basingstoke, United Kingdom). Results were interpreted
according to the Clinical and Laboratory Standards Institute
(CLSI) interpretative criteria (CLSI, 2012). In addition, isolates
displaying resistance to cefoxitin (30 µg) and cefotaxime (30 µg)
or ceftazidime (30 µg), were considered presumptive AmpC
producers (CLSI, 2012). To demonstrate the co-production of
ESBL and AmpC β-lactamase, cefoxitin resistant isolates were
further tested with cefepime (30 µg) and cefepime/clavulanic
acid (30/10 µg). E. coli ATCC 25922 was used as control strain
for susceptibility testing, whilst ESBL and pAmpC producing
E. coli isolates, previously confirmed by PCR and sequencing,
were used as positive controls for the phenotypic ESBL/AmpC
testing. Ertapenem (10 µg) and meropenem (10 µg) were also
included routinely for carbapenem-resistance screening whilst
ciprofloxacin (5 µg) and enrofloxacin (5 µg) were used for
confirming fluoroquinolone-resistance in isolates typed to the
ST131 H30Rx lineage.
Characterization of ESBL and pAmpC
Resistance Genes
Cell lysates obtained from all investigated isolates were screened
by PCR product sequencing for the presence of genes encoding
for β-lactamases (blaCTX−M, blaSHV, blaTEM, blaOXA) and
plasmid-mediated blaAmpC variants (ACC, FOX, MOX, DHA,
CIT, and EBC) as previously described (Essack et al., 2001; Pérez-
Pérez and Hanson, 2002; Dallenne et al., 2010). DNA sequencing
was performed on amplicons for all the CTX-M and pAmpC
positive isolates. For this, PCR amplicons were purified with the
Macherey-Nagel NucleoSpin Gel and PCR Clean-up (Thermo
Fisher Scientific, United Kingdom). The nucleotide sequences
were compared with those present in GenBank1 to identify the
specific gene variants involved.
1https://blast.ncbi.nlm.nih.gov/Blast.cgi
Molecular Typing
An extended PCR scheme described by Clermont et al. (2013) was
used to assign the ESBL/AmpC E. coli isolates to one of the seven
phylogenetic groups (A, B1, B2, C, D, E, F). Isolates not matching
any of the profiles of the initial quadruplex scheme were recorded
as Unknown phylogroup (U). Selected CTX-M-positive isolates
[at least one from each site of infection and carrying unique
resistance genes combinations (i.e., blaCTX−M and blaTEM,
or blaCTX−M and blaSHV)] were further typed by multi-locus
sequence typing (MLST) which was performed as previously
described (Wirth et al., 2006). All isolates which typed to
phylogroup B2 were screened for the presence of the O25b-ST131
clone by allele-specific PCR (Clermont et al., 2008). Identification
of E. coli ST131 clade, including the subclade C/H30, C/H30-
R with its H30Rx and non-Rx sublineages was performed by
PCR-based multiplex ST131 clade assay (Matsumura et al., 2017).
Virulence Gene and Extraintestinal
Pathogenic E. coli (ExPEC)
Characterization
All ESCR isolates were screened by a multiplex PCR assay
designed to detect virulence markers likely to be associated with
extraintestinal pathogenic E. coli (ExPEC) (Johnson et al., 2015).
ExPEC status was assigned according to the definition proposed
by Johnson and Russo (2005) which defined ExPEC isolates on
the basis of the presence of≥2 virulence associated genes (VAGs)
or gene sets, including papAH and/or papC, sfa/focDE [central
region of sfa (S fimbriae) and foc (F1C fimbriae) operons],
afa/draBC (Dr antigen-binding adhesins), kpsMII (group II
capsule Polysaccharides), and iutA (ferric aerobactin receptor)
(Johnson et al., 2015). A virulence score was assigned to each
isolate based on the number of virulence genes detected, with pap
elements counting collectively as a single trait.
Clinical and Paraclinical Data
To evaluate the likelihood of ESCR E. coli isolates being
associated with clinical infections, overall bacterial culture
results (including results of repeated sampling from the same
case), hematological results (where available) and clinical data
were collated. From these data, and after reviewing referral
letters, patient’s clinical finding and ancillary tests, which were
available in 146/164 cases, a decision of evidence of infection
was made for each case. Confirmation of association with
infection was provided by the presence of at least one of the
following: rods/coccobacilli in cytology smears (either Diff-quick
or Gram-stained), raised peripheral white blood cell count, raised
inflammatory markers (C-reactive protein when tested) and/or
the final clinical diagnosis of infection. Where none of these
criteria were met and the isolate was obtained from a mixed
bacterial culture, the isolation of an ESBL/AmpC-producing
E. coli was considered to be due to contamination.
Statistical Analysis
GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego,
CA, United States) was used for data analysis. We used
the chi-squared test to assess the correlation between ExPEC
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status, phylogroup and presence of antimicrobial resistance
genes. Mann–Whitney U test was used to assess the virulence
factor score correlation with phylogroup and presence of
antimicrobial resistance genes. P-value < 0.05 was considered
statistically significant.
RESULTS
Prevalence of ESCR, ESBL, and pAmpC
Producing E. coli Isolates
During the study period (January 2010–August 2016), 876 E. coli
isolates (dogs n = 748, cats n = 76 and horses n = 52) were
obtained from the clinical specimens submitted from companion
animals. Of these, ESCR was identified in 164 (18.7%) non-
repetitive E. coli isolates obtained from dogs (n = 138), cats (n = 8)
and horses (n = 18) which displayed inhibition zones (≤25 mm)
for cefpodoxime (CPD) with or without cefoxitin resistance.
The ESCR E. coli isolates were cultured from urine (n = 49),
wound swabs (n = 41), GI tract samples, mainly feces from
diarrheic animals (n = 30), skin infections or otitis cases (n = 23),
body fluids or tissue biopsies (n = 9), bile or liver samples
(n = 12). Combination disc tests for phenotypic ESBL testing of
the 164 ESCR isolates resulted in 53 isolates displaying an ESBL
phenotype (53/164, 32.3%), 67 isolates showed a presumptive
AmpC phenotype (67/164, 40.9%) and 11 isolates (11/164, 6.7%)
demonstrated a phenotype suggesting mixed ESBL/AmpC co-
production (resistance to cefoxitin, cefotaxime or ceftazidime
and demonstrating synergy when tested with cefepime, a fourth
generation cephalosporin and cefepime/clavulanic acid). Thirty-
three ESCR isolates (33/164, 20.0%) produced inconclusive
phenotypic ESBL/pAmpC results (Table 1). No carbapenem-
resistance was detected in the ESCR isolates.
Molecular Characterization of
ESBL/pAmpC Genes
Overall, ESBL and/or pAmpC encoding genes were found in
79.9% (131/164) of the ESCR E. coli isolates. blaCTX−M genes were
the most common ESBL genotype (48.9%, 64/131) of which the
most prevalent were blaCTX−M−15 (46.9%, 30/64), blaCTX−M−14
(21.9%, 14/64), and blaCTX−M−55 (12.5%, 8/64). blaCTX−M−1
and blaCTX−M−24 were each found in four isolates; blaCTX−M−28
was found in three isolates whilst only one blaCTX−M−27 E. coli
isolate was identified in a liver tissue biopsy from a dog.
In addition, blaSHV−12 (n = 2) was detected in two isolates,
which both co-harbored CTX-M genes (blaCTX−M−55 and
blaCTX−M−24, respectively). The vast majority of CTX-M-type
ESBL producing isolates also carried blaTEM (n = 29/64) and/or
blaOXA (n = 23/64). A number of ESCR isolates (n = 18/164)
only produced TEM or OXA β-lactamases whilst in 15/164
isolates, most of which belonged to phylogroup B2 (n = 12/15),
none of the investigated bla genes were detected. Resistance to
ESC via plasmid mediated AmpC genes was detected in 51.2%
(67/131) of the ESBL and/or pAmpC producing isolates, where
blaCMY−2 was the most common pAmpC gene identified (59/67),
whilst in some isolates pAmpC genes were co-harbored with
blaCTX−M−15 (n = 8), blaCTX−M−24 (n = 2) or blaCTX−M−55
(n = 1). Additionally, blaDHA and blaEBC were detected in seven
canine isolates and three equine isolates, respectively. No blaACC,
blaMOX or blaFOX plasmid mediated AmpC resistance genes were
detected in the investigated isolates.
Molecular Typing of E. coli Isolates
Phylogenetic group B2, which is associated with extra-intestinal
infections in humans, was the most commonly identified
phylogroup among the ESCR E. coli isolates (33.5%, 55/164);
phylogroups D and F, which are closely related, and can also
be associated with extra-intestinal infections, represented 12.20%
(20/164) of the isolates. The phylogroups generally regarded as
commensal strains (A, B1) were also associated with ESCR where
phylogroup B1 was the most predominant (n = 35, 21.3%), closely
followed by phylogroup A (n = 31, 18.9%), C (n = 19, 11.5%),
and U (n = 4, 2.4%).
MLST typing identified ST410, recently reported as a new
successful pandemic clone (Schønning et al., 2018), as the
most prevalent amongst ESBL/pAmpC producing and MLST
tested isolates (6/131, all phylogroup C), three of which were
both CTX-M- and pAmpC –producers. ST410 was identified
in isolates obtained from five dog clinical specimens [urine
(n = 2), abdominal fluid (n = 2), tissue biopsy] and one from
a horse abdominal fluid isolate. In addition, other important
human E. coli clones involved in ESBL dissemination were
identified amongst CTX-M-producers such as ST10 in four dog
isolates, three CTX-M-14 and one CTX-M-15 producers, all
phylogroup A, obtained from wound, urine (n = 2) and tissue
biopsy; ST167 in one CTX-M-15 and two CTX-M-55 dog isolates
from wound, feces and urine, and also one equine CTX-M-15
producing horse isolate obtained from a wound swab; ST648
(phylogroup D) was identified in one isolate obtained from an
interdigital abscess from a dog.
Five E. coli isolates were typed to ST131-B2 (5/164, 3.1%)
by both allele specific PCR and MLST and were CTX-M-15, -
14, -55, or -27 producers. All ST131-B2 isolates were from dogs
with three isolates from sterile sites (two from bile, one from
urine) whilst two isolates were from a colon biopsy and a skin
swab. ST131-clade specific PCR showed that 4/5 ST131 isolates
belonged to Clade C/H30; by using the same assay, one isolate
carrying blaCTX−M−27 was typed to the recently described sub-
clade C1-M27; three isolates carrying blaCTX−M−15 and showing
fluoroquinolone resistance were typed to the subclade C2 known
as H30Rx (C2/H30Rx). The remaining ST131 isolates carried
blaCTX−M−55 and demonstrated fluoroquinolone resistance but
remained unclassified by this assay.
Virulence Score (VS) and ExPEC
Status of ESCR Isolates
The majority of ESCR E. coli isolates included in this study were
obtained from non-GI tract sites (103/131, 81.7%). As expected,
most of the isolates with virulence factor (VF) scores >2
belonged to phylogroup B2 (32/55 isolates, 58%) and phylogroup
D and F (in 5/20 isolates, 25%), followed by phylogroup A
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TABLE 1 | Phenotypic and genotypic characterization of extended-spectrum cephalosporin resistant Escherichia coli isolates obtained from companion animals
clinical specimens.
Phenotype β-lactamases
enzyme
Number of
isolates
Phylogroup ST Year of
isolation
Source Body site
ESBL (n = 53) CTX-M-15 7 A, B1 (n = 4)
B2 (n = 2)
U (n = 1)
86 (1)
23 (1)
623 (1)
3880 (1)
4184 (1)
2010 (n = 1),
2013 (n = 1),
2014 (n = 3)
Dog (n = 5),
Horse (n = 2)
GI tract (n = 3),
SI/O (n = 1),
Urine (n = 1),
Wound (n = 2)
CTX-M-15,
OXA
10 A, B1 (n = 2)
B2 (n = 3)
C (n = 4)
D (n = 1)
131 (3)
167 (1)
1284 (1)
2348 (1)
2010 (n = 4),
2011 (n = 3),
2012 (n = 1)
Dog (n = 9),
Horse (n = 1)
GI tract (n = 4),
Hepato-biliary
(n = 1),
Urine (n = 1),
SI/O (n = 3),
Wound (n = 1)
CTX-M-15,
TEM,
OXA
2 D (n = 1)
F (n = 1)
648 (1) 2011 Dog BF/BP (n = 2),
SI/O (n = 3)
CTX-M-15,
TEM
3 A 10 (1)
167 (1)
2011 Dog Wound (n = 3)
CTX-M-14 6 A (n = 3)
B2 (n = 2)
C (n = 1)
10 (2)
95 (1)
209 (1)
2012 (n = 2)
2014 (n = 1),
2015 (n = 3)
Dog (n = 2),
Cat (n = 1),
Horse (n = 1)
GI tract (n = 1),
SI/O (n = 1),
Urine (n = 4)
CTX-M-14,
TEM
8 A (n = 7),
D (n = 1)
10 (1)
209 (1)
617 (2)
2010 (n = 5),
2015 (n = 2),
2016 (n = 1)
Dog (n = 8) BF/BP (n = 2),
Hepato-biliary
(n = 2)
GI tract (n = 1),
Urine (n = 3)
CTX-M-55 2 B2 (n = 2) 1340 (2) 2015 (n = 2) Dog (n = 2) GI tract (n = 2)
CTX-M-55,
TEM
3 A (n = 1)
B2 (n = 2)
167 (1)
1340 (2)
2015 (n = 2),
2016 (n = 1)
Dog (n = 3) Urine (n = 2),
GI tract (n = 1),
CTX-M-55,
OXA
1 B2 131 2015 Dog Urine
CTX-M-55,
TEM, SHV-12
1 B1 5036 2013 Horse Wound
CTX-M-1 3 B1 (n = 2)
D
4792
3509
2013 (n = 2)
2014 (n = 1)
Dog GI tract
CTX-M-1, TEM 1 B1 641 2013 Horse Wound
CTX-M-27 1 B2 131 2010 Dog Hepato-biliary
CTX-M-28,
TEM
3 B1 (n = 3) 3743
448 (2)
2015 Dog (n = 2),
Horse (n = 1)
SI/O (n = 2),
Wound (n = 1)
CTX-M-24,
TEM
1 A – 2014 Dog Wound (n = 1)
CTX-M-24,
OXA
1 C 3163 2012 Dog Wound (n = 1)
AmpC (n = 67) CMY-2 23 B1 (n = 4)
B2 (n = 9)
C/F (n = 3)
D (n = 7)
– 2010 (n = 2),
2011 (n = 1),
2012 (n = 6)
2013 (n = 4),
2014 (n = 5),
2015 (n = 4),
2016 (n = 1)
Dog (n = 23) Wound (n = 7),
Urine (n = 6),
GI tract (n = 5),
SI/O (n = 4),
Hepato-biliary
(n = 1)
CMY-2, TEM 30 A/B1 (n = 12)
B2 (n = 12)
C (n = 3)
F (n = 3)
2348 (1) 2010 (n = 1),
2011 (n = 2),
2012 (n = 12)
2013 (n = 4),
2014 (n = 4),
2015 (n = 6)
Dog (n = 28),
Cat (n = 1),
Horse (n = 1)
Urine (n = 15),
GI tract (n = 5),
Wound (n = 4),
BF/BP (n = 3),
Hepato-biliary
(n = 2),
SI/O (n = 1)
(Continued)
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TABLE 1 | Continued
Phenotype β-lactamases
enzyme
Number of
isolates
Phylogroup ST Year of
isolation
Source Body site
CMY-2, TEM,
OXA
3 B2 (n = 1)
C (n = 1)
D (n = 1)
410 (1) 2012 (n = 1),
2013 (n = 2)
Dog Urine (n = 1),
SI/O (n = 1),
GI tract (n = 1)
CMY-2, OXA 2 A (n = 1)
C (n = 1)
– 2010 (n = 1),
2012 (n = 1)
Dog (n = 2) Wound (n = 2)
CMY-2, TEM,
DHA
1 B2 – 2015 Dog SI/O
DHA 1 B1 – 2015 Dog Wound
DHA, TEM 3 A/B1 (n = 2)
F (n = 1)
– 2013 (n = 1),
2015 (n = 1),
2016 (n = 1)
Dog Hepato-biliary
(n = 1), Urine
(n = 1), Wound
(n = 1)
DHA, TEM,
OXA
1 B1 – 2015 Dog Wound
EBC 1 B2 – 2014 Horse Wound
EBC, TEM 2 B2 – 2014 Horse Wound (n = 2)
ESBL/AmpC(n = 11) CTX-M-15,
OXA, CMY-2
4 B2 (n = 1)
C (n = 3)
1485 (1) 2012 (n = 3),
2013 (n = 1)
Dog BF/BP (n = 1),
SI/O (n = 1),
Urine (n = 1),
Wound (n = 1)
CTX-M-15,
TEM,
OXA, CMY-2
3 B2 410 (1)
3163 (1)
2011 (n = 1),
2012 (n = 2)
Dog GI tract
CTX-M-15,
TEM, OXA,
DHA
1 D – 2013 Dog SI/O
CTX-M-24,
CMY-2, TEM,
OXA
1 U – 2013 Dog Hepato-biliary
CTX-M-24,
CMY-2, TEM,
SHV-12
1 C 410 2013 Horse BF/BP
CTX-M-55,
TEM, CMY- 2
1 A 167 2013 Dog GI tract (n = 1)
Inconclusive phenotype (n = 33) TEM,
OXA
1 B1 – 2014 Dog Bile
TEM 13 A/B1 (n = 10)
B2 (n = 2)
U (n = 1)
– 2010 (n = 2),
2011 (n = 1),
2012 (n = 1),
2013 (n = 1),
2014 (n = 3),
2015 (n = 2),
2016 (n = 3)
Dog (n = 8),
Cat (n = 2),
Horse (n = 3)
BF/BP (n = 1),
GI tract (n = 2),
SI/O (n = 2),
Urine (n = 5),
Wound (n = 3)
OXA 4 B1 (n = 1),
F (n = 2),
U (n = 1)
– 2012 (n = 3),
2014 (n = 1)
Dog (n = 3),
Horse (n = 1)
Wound (n = 2),
Urine (n = 1),
SI/O (n = 1)
– 15 B1 (n = 2)
B2 (n = 12)
C (n = 1)
– 2010 (n = 1),
2011 (n = 1),
2012 (n = 1),
2013 (n = 2),
2014 (n = 3),
2015 (n = 5),
2016 (n = 2)
Dog (n = 11),
Cat (n = 4)
Urine (n = 7),
Wound (n = 3),
SI/O (n = 3)
Hepato-biliary
(n = 2)
ST, sequence type by multi-locus sequence typing; BF/BP, body fluids/biopsies; SI/O, skin infection/otitis.
(5/31 isolates 16%), phylogroup C 19 isolates (2/19 isolates 10.5%)
and phylogroup B1 (3/35 isolates8.6%).
P fimbrial structural subunits encoded by papA, papC or
papE (75/164, 45.7%) were the most commonly identified
virulence genes, followed by iutA (61/164, 37.2%), which
encodes for a ferric aerobactin receptor involved in the iron
uptake and kpsII gene (42/164, 25.6%) which is involved in
capsular polysaccharide production. The B2 phylogroup showed
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a significantly higher virulence score compared to all the other
groups (p < 0.01) and more than half of B2 strains (32/55)
where defined as ExPEC. Phylogroups D and F, which can also
be associated with ExPEC, demonstrated a higher virulence score
compared to isolates belonging to group A, B1, C, and U but this
difference was not statistically significant (Table 2).
Analysis of virulence factor scores, in relation to carriage
of resistance genes, also showed differences in the frequency
of virulence genes amongst isolates carrying or lacking
ESBL/pAmpC genes. In particular, the ExPEC status and
virulence score average were higher for isolates lacking the
screened ESBL/pAmpC resistance genes (here defined as isolates
with an inconclusive phenotype) and lower for isolates possessing
both ESBL and AmpC genes (p< 0.05) (Table 2).
Body Site Distribution
Analysis of the frequency of ESBL/pAmpC genotypes according
to the site of isolation, shows that isolates from the GI tract,
hepatobiliary infections and urine carry a greater variety of
ESBL/pAmpC resistance genes compared to isolates from the
skin/soft tissue infections, body fluids and wound infections
(Figure 1A). With regard to the host species involved, horse
isolates showed a wider variety of bla genes despite the low
numbers of isolates compared to canine isolates (Figure 1B).
However, blaCTX−M−15 was the predominant ESBL genotype
identified in both canine and equine isolates (19.9 and 16.6% of
isolates, respectively), as well as in GI tract (35.7%), skin/otitis
isolates (31.6%) and wound isolates (19.2%) from cats and
dogs. CTX-M-14 β-lactamase producers, although rare in wound
infections and GI tract isolates (0 and 2%, respectively), were
a relatively common ESBL type found in isolates from body
fluids/biopsy samples (25.0%), hepatobiliary infections (18.2%),
and urine (15.9%). In addition, around half of the ESCR isolates
obtained from dogs harbored pAmpC genes (72/138, 52.2%),
either alone or in combination with other β-lactamase encoding
genes, with frequencies ranging from 36% for hepatobiliary
infections to 55% in the case of urine samples. Moreover,
blaCMY−2 alone or in combination with blaTEM was the most
common genotype associated with ESCR E. coli isolates from UTI
from dogs (23/46, 50.0%).
Clinical/Paraclinical Data Analysis
Clinical or laboratory data used to evaluate evidence of infection
was available in 111 of 146 cases (76.0%). Overall, 70 ESCR
E. coli isolates were obtained from normally sterile body
sites (body fluids/biopsy, urine collected by cystocentesis and
hepatobiliary samples) and 54 of these were pure cultures
(54/70, 77.1%). Whereas from 94 ESCR isolates, obtained from
body sites populated with commensal flora (skin, ear canal, GI
tract), only 14 E. coli isolates were obtained in pure growth
(14/94, 14.8%) (p< 0.0001).
Bacterial culture results of ESCR E. coli isolates (Table 3),
also shows that the vast majority of the isolates originating
from urinary tract infections (UTIs) were obtained in pure
culture (45/49, 91.8%) and in almost half of the cases, the
clinical records showed repeated isolation of an ESBL/AmpC
producing isolate (20/49, 40.8%) indicating persistence or re-
infection; this was significantly higher than the frequency of
repeated isolation from skin/ear infections (p = 0.0029) and GI
tract (p < 0.00001). In addition, in the majority of UTI cases
where an ESCR E. coli isolate was obtained (30/49, 61.2%), there
was at least one clinical or paraclinical test result supportive
of infection (either rods on cytology, hematuria or pollakiuria,
neutrophilia). However, in 11 UTI cases (11/49, 22.4%) isolation
TABLE 2 | Distribution of average virulence scores and ExPEC status in relation to their phylogroups and resistance genes identified.
Phylogroup n (%) ESBL/AmpC type n (%)
Additional
CTX-M CTX-M- β-lactamase Inconclusive
A/B1 B2 D and F C and U group 1 group 9 AmpC ESBL/AmpC producers phenotype∗
(n = 66) (n = 55) (n = 20) (n = 23) (n = 36) (n = 18) (n = 67) (n = 11) (n = 18) (n = 15)
Average
virulence
score 0.76 2.70 1.00 0.91 1.11 1.82 1.28 0.7 1.47 3.4
hlyD 1 14 1 0 2 1 6 0 2 5
papA 4 17 1 2 3 6 8 0 2 5
kpsII 3 29 8 2 9 2 20 1 4 6
iutA 26 18 6 11 17 9 20 6 8 1
papC 6 16 0 3 2 6 7 0 3 7
sfa1 3 16 1 1 1 1 8 0 3 8
afa1 0 2 0 0 2 0 0 0 0 0
papE 6 18 2 2 2 6 6 0 5 9
cnf1 3 17 0 0 3 1 6 0 1 9
ExPEC 8 (12.12%) 32 (58.18%) 5 (25.00%) 3 (13.05%) 8 (22.22%) 8 (44.44%) 13 (19.40%) 0 (0%) 6 (33.33%) 8 (53.33%)
ExPEC, extraintestinal pathogenic E. coli, defined operationally as the presence of >2 of the virulence genes investigated (papA and/or papC, counted as one). ∗ Isolates
lacked all beta-lactam resistance genes, which they were screened for.
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FIGURE 1 | Diversity and distribution of ESBL and pAmpC producing Escherichia coli according to the clinical specimens (A) and species (B).
GI, Gastrointestinal tract.
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TABLE 3 | Clinical and laboratory data associated with extended-spectrum cephalosporin resistant Escherichia coli clinical isolates.
Phylogroup(s)
(n)
VF ST
(n- if >1 isolates)
ESBL/AmpC
Beta-lactamase
Narrow-spectrum
beta-lactamase
Type of
growth
Repeat
isolation
Evidence of
clinical
infection
≥2(n) ≤2(n) Pure (n) Mixed (n) Yes (n) No (n) Yes (n) No (n)
Urine (n = 49) B2 (16) 1 CTX-M-14 15 1 3 12 10 5
1 1 ST1340; ST131 CTX-M-55 TEM (1)
OXA (1)
5 1 CMY-2 TEM (4)
2 TEM
5 –
D and F (6) 1 DHA TEM 6 0 3 2 4 0
4 CMY-2 TEM (1)
1 CTX-M-14 TEM
A (6) 1 ST167; CTX-M-55 5 1 4 2 5 1
4 1 ST10 (2); ST209 (2);
ST617
CTX-M-14 TEM (3)
B1 (15) 1 ST23 CTX-M-15 14 1 8 7 7 4
1 8 CMY-2 TEM (8)
1 2 TEM (2),
OXA (1)
2
C (5) 1 CTX-M-15,
CMY-2
OXA 4 1 2 3 4 1
1 ST410 CTX-M-15 OXA
1 2 ST410 (1) CMY-2 TEM (3),
OXA (1)
U 1 TEM 1 0 – – – –
Total 22 27 45 4 20 26 30 11
Body fluid/
biopsies (n = 9)
B2 (1) 1 CMY-2 TEM 0 1 1 0 1 0
F (2) 1 CTX-M-15 TEM, OXA 1 1 0 2 1 0
1 ST2348 CMY-2 TEM
A (4) 1 TEM 1 3 2 1 3 0
1 1 ST10, ST617 CTX-M-14 TEM (2)
1 CMY-2 TEM
C (2) 1 ST410 CTX-M-15,
CMY-2
OXA 2 0 1 1 2 0
1 ST410 CMY-2, SHV TEM
Total 2 7 4 5 4 4 7 0
Hepato-biliary
(n = 12)
B2 (4) 1 ST131 CTX-M-27 3 1 1 3 4 0
1 ST131 CTX-M-15 OXA
1 CMY-2
1
F (1) 1 CMY-2 TEM 1 0 0 1 0 1
A (3) 2 CTX-M-14 TEM (2) 0 3 0 3 3 0
1 DHA TEM
B1 (1) 1 TEM, OXA 0 1 1 0 1 0
C (2) 1 CMY-2 TEM 1 1 1 1 1 1
1
U (1) 1 CTX-M-24,
CMY-2
TEM, OXA 0 1 1 0 1 0
Total 3 9 5 7 4 8 10 2
(Continued)
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TABLE 3 | Continued
Phylogroup(s)
(n)
VF ST
(n- if >1 isolates)
ESBL/AmpC
Beta-lactamase
Narrow-spectrum
beta-lactamase
Type of
growth
Repeat
isolation
Evidence of
clinical
infection
≥2(n) ≤2(n) Pure (n) Mixed (n) Yes (n) No (n) Yes (n) No (n)
Skin
infection/otitis
(n = 23)
B2 (11) 2 ST131, ST3880 CTX-M-15 OXA (1) 1 10 1 9 10 0
1 ST1485 CTX-M-15,
CMY-2
OXA
1 ST95 CTX-M-14
2 2 CMY-2 TEM
3
D and F (3) 1 1 ST2348 CTX-M-15 TEM (1), OXA (2) 0 3 0 2 2 0
1 CMY-2 TEM, OXA
A (2) 2 TEM (2) 0 2 1 0 1 0
B1 (5) 1 ST4792 CTX-M-1 0 5 0 4 3 1
2 ST448 (2) CTX-M-28 TEM (2)
2 CMY-2 TEM (1)
C (1) 1 CTX-M-15 OXA 0 1 1 0 1 0
U (1) 1 OXA 0 1 0 1 1 0
Total 9 14 1 22 3 16 18 1
GI tract (n = 30) B2 (15) 1 1 ST131; ST623 CTX-M-15 OXA (1) 3 12 3 12 8 7
2 ST3163 (2) CTX-M-15,
CMY-2
TEM (2), OXA (2)
2 1 ST1340 (2) CTX-M-55 TEM (1)
2 6 CMY-2 TEM (5), OXA (1)
D (1) 1 ST3509 CTX-M-1 05 1 0 1 0 1
A (6) 1 CMY-2 TEM 0 5 0 5 1 4
2 ST1284; ST4184 CTX-M-15 OXA (1)
1 ST617 CTX-M-14 TEM
1 ST167 CTX-M-55,
CMY-2
TEM
1 TEM
B1 (3) 2 CMY-2 1 2 0 2 2 0
1 TEM
C (4) 1 ST410 CTX-M-15,
CMY-2
TEM, OXA 0 4 0 4 2 2
2 CTX-M-15 OXA (2)
1 CTX-M-14
U (1) 1 CTX-M-15 0 1 0 1 1 0
Total 5 25 4 25 3 25 14 14
Wound (n = 41) B2 (8) 1 1 CMY-2 TEM (2) 0 8 1 7 7 1
3 EBC TEM (2)
2 1
D and F (7) 2 OXA 1 6 1 6 6 1
5 CMY-2
A (10) 1 CTX-M-24 TEM 3 7 3 7 7 3
2 CTX-M-15, DHA
or CMY
TEM, OXA
(Continued)
Frontiers in Microbiology | www.frontiersin.org 10 June 2019 | Volume 10 | Article 1260
fmicb-10-01260 June 4, 2019 Time: 10:32 # 11
Bortolami et al. ESBL- and pAmpC-Producing Escherichia coli in Companion Animals
TABLE 3 | Continued
Phylogroup(s)
(n)
VF ST
(n- if >1 isolates)
ESBL/AmpC
Beta-lactamase
Narrow-spectrum
beta-lactamase
Type of
growth
Repeat
isolation
Evidence of
clinical
infection
≥2(n) ≤2(n) Pure (n) Mixed (n) Yes (n) No (n) Yes (n) No (n)
3 ST167, ST10 CTX-M-15 OXA (1), TEM (2)
2 CMY-2 OXA (1), TEM (1)
2 TEM
C (5) 1 ST410 CTX-M-15,
CMY-2
OXA 1 4 2 3 4 1
1 ST3163 CTX-M 24 OXA
3 CMY-2 OXA (1)
B1 (11) 1 1 ST641 CTX-M-1 TEM (1) 4 7 2 6 6 2
2 ST86 CTX-M-15
1 ST3743 CTX-M-28 TEM
1 ST5036 CTX-M-55, SHV TEM
3 DHA OXA (1), TEM (2)
1 CMY-2 TEM
1
Total 7 34 9 32 9 29 30 8
ST, sequence type by multi-locus sequence typing; VF, virulence factor score.
of ESBL/pAmpC producing bacteria was not accompanied by
clinical signs, suggesting transient colonization of the bladder or
urinary tract or possibly subclinical infection; clinical/paraclinical
data was missing in 8 UTI cases. In contrast, the majority of
ESCR isolates from skin infections/otitis, GI tract and wounds
were obtained in mixed cultures (80/94, 85.1%). The role played
by the ESCR or specifically the ESBL/AmpC producing bacteria is
difficult to ascertain in samples yielding a mixed bacterial growth
(polymicrobial cultures often with other Gram-negative bacteria
also involved); however, in most of these cases (64/94, 69.1%)
there was clinical evidence of infection (mainly inflammation and
purulent discharge).
Analysis of E. coli phylogroups in relation to the infection
site and carriage of resistance genes, shows that the phylogroups
usually associated with ExPEC (B2, D, and F) and those regarded
as commensals (A, B1, C), were both associated with ESCR
and ESBL/AmpC production and were isolated in largely similar
proportions from UTIs (22 versus 27), hepatobiliary infections
(5 versus 7), GI tract specimens (16 versus 14); however,
higher numbers of the ExPEC associated phylogroups (B2, D,
and F) were found amongst skin infections and otitis isolates
(14 versus 9) and lower numbers amongst body fluids/biopsy
isolates (3 versus 6) and wound infections (15 versus 26)
(Table 3). Analysis of VF distribution among these two groups
[likely ExPEC (B2, D, and F) versus likely commensal (A, B1,
and C)] shows that, with the exception of UTI isolates, where
there were a similar number of isolates from the two groups
with a VF ≥ 2, in general isolates of phylogroups B2, D, and F
carried more virulence genes (≥2); this was observed especially
in hepatobiliary, skin infections and GI tract isolates. In addition,
clinical data analysis also showed that in 70.6% of the infections
associated with ESCR E. coli of phylogroup B2, D, and F there was
clinical/paraclinical evidence of an active infection.
DISCUSSION
Despite the increasing prevalence of ESBL/pAmpC producing
Enterobacteriaceae reported in animals and the increasing
rate of isolation by veterinary laboratories, there is still little
information regarding the role that ESBL/AmpC producing
E. coli isolates play as infectious agents in diseased companion
animals. Many studies have investigated the zoonotic risks
and the prevalence of fecal carriage or have characterized
the ESBL/AmpC producing isolates from clinical specimens in
animals (Dierikx et al., 2012; Hordijk et al., 2013; Maeyama
et al., 2018; Zogg et al., 2018). However, very few studies
(mainly human) have linked the molecular characteristics of
ESBL/pAmpC producing isolates with clinical data in order to
determine the clinical significance of ESCR E. coli (Sidjabat
et al., 2009; Schoevaerdts et al., 2011; Rodríguez-Baño et al.,
2012). Thus, the current study investigated the molecular
characteristics of ESBL/pAmpC producing E. coli isolates from
various companion animal infections in relation to clinical and
paraclinical information, which could provide an indication of
their role as infecting agents or occasional contaminants in
clinical specimens. Comparison with our previous work shows
an important increase of ESCR E. coli prevalence in clinical
isolates investigated in our laboratory over time, with a rise from
7% (2010/2011) (Timofte et al., 2016) to 21% in the current
study (samples from 2010/2016), highlighting the need for greater
understanding of their association with infection in order to
improve disease management and infection control.
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Molecular characterization has shown that ST410 was the
most common ST identified in clinical isolates from dogs and
horses in this study, both in CTX-M- and pAmpC producers
which is concerning given that this clone was recently described
as a high-risk multi-drug resistant (MDR) clone with increased
potential for inter-species transmission (Schaufler et al., 2016).
Also, recently attention has been drawn to the emergence of
E. coli D-ST648 in companion animals, a clone which combines
characteristics of multidrug resistance and virulence, similar to
those observed in E. coli ST131-B2 (Ewers et al., 2014). In
our study, we describe the isolation of a D-ST648-CTX-M-15
E. coli from an interdigital abscess from a dog, and to the
best of our knowledge, this has not been reported previously
in United Kingdom animals. The pandemic virulent E. coli
ST131-B2 clone was rare among the ESCR isolates analyzed (five
isolates); nonetheless, its isolation occurred in three different
years (2010, 2011, and 2015) which suggests persistence in animal
populations and raises the potential of zoonotic risks represented
by ESBL-producing E. coli in companion animals. Previous
studies have shown that ST131-B2 has driven the dissemination
of the CTX-M β-lactamase (particularly CTX-M-15) worldwide
(Petty et al., 2014) and recent epidemiologic and whole genome
phylogeny studies have shown that the clonal structure of E. coli
ST131 is highly variable including subclones with particular
resistance traits (Price et al., 2013). These studies have also
shown that specific sublineages are particularly responsible
for ST131/CTX-M-15 dissemination, especially those recently
named as clone C or C/H30, which encompasses two sublineages
[C/H30-R (non-Rx) and C2/H30Rx] both characterized by
fluoroquinolone resistance (Matsumura et al., 2017). In our
study, one blaCTX−M−27 positive isolate was typed to the C1/H30-
R (recently described as the C1-M27 sublineage) and three
blaCTX−M−15 and fluoroquinolone resistant isolates were typed to
the C2/H30Rx sublineage. The C1-M27 clone is responsible for
the epidemic spread of ST131-CTX-M-27 in Japan (Matsumura
et al., 2015) where a high prevalence of E. coli ST131 H30R/non-
Rx lineage (likely the C1-M27 sublineage) was also found in
isolates from dogs (Maeyama et al., 2018). A recent study looking
at the prevalence and characteristics of ST131 clone among
ESBL-producing E. coli colonized patients from four European
hospitals, also showed a changing epidemiology of ST131 in
Europe and the emergence of C1-M27 clade (Merino et al., 2018).
Ghosh et al. (2017) examined the presence of ST131-CTX-M-27
producing E. coli amongst isolates from the environment, food,
livestock, humans, and companion animals in Germany and
found that this lineage was exclusively found in human isolates
and showed an increasing prevalence from 0 to 45% over a period
of 7 years. E. coli ST131 H30/H30-Rx subclones causing UTI in
companion animals in Europe have been previously reported in
companion animals from Portugal (Belas et al., 2018) but to the
best of our knowledge, this is the first report of ST131 C1-M27
sublineage in companion animals outside Japan.
Overall, the molecular characterization of resistance genes
and genetic background of the isolates analyzed this study has
identified a diversity of blaCTX−M genes in E. coli isolates.
The blaCTX−M variants, CTX-M-14 and CTX-M-15 generally
predominate amongst human and animal E. coli isolates;
however, our study shows a decreasing occurrence of CTX-M-15
β-lactamase producers over the last few years in favor of new
variants, in particular CTX-M-55. In the United Kingdom, this
latter blaCTX−M variant has been isolated from turkey meat
(Randall et al., 2014; Parker et al., 2016), but it was not previously
identified from companion animals in the United Kingdom
or Europe. However, CTX-M-55 is among the predominant
gene type in E. coli isolated from companion animals in Asian
countries (Kawamura et al., 2017).
Phylogroup typing of ESCR E. coli isolates showed a high
occurrence of B2 strains (33.5%) which is markedly higher
than the frequency reported in a similar study conducted in
Germany where 2.4% of the strains were assigned to this
phylogroup (Schmiedel et al., 2014; Wagner et al., 2014).
B2 strains are frequently associated with a higher number of
virulence determinants (Valentin et al., 2014) and as expected,
the virulence score of B2 strains (and to a lesser extent D and F)
in this study was markedly higher than of other phylogroups;
therefore, isolates typed to phylogroup B2, D, or F were more
frequently classified as ExPEC. Furthermore, in the majority of
the infections associated with phylogroups B2, D, and F there
was clinical/paraclinical evidence of infection that supports their
association with true infection. The average virulence score in the
ESCR isolates was lower in isolates carrying both ESBL/pAmpC
genes (VS = 0.7) and higher in isolates lacking these genes
and categorized as inconclusive phenotype (VS = 3.4). This
is in accordance with the general concept that in most cases,
increased resistance in E. coli isolates can be associated with
decreased virulence due to survival fitness costs (Beceiro et al.,
2013). However, the existence of already established (ST131) or
emerging (ST648) clones combining virulence and multidrug-
resistance via production of CTX-M β-lactamase (Ewers et al.,
2014; Petty et al., 2014), provides the evidence that the opposite
is also true and occurrence of such clones in companion animals
clinical specimens is worrying both due to therapeutic limitations
and public health concerns.
With regards to the body site distribution of isolates carrying
different ESBL/pAmpC genes, it is interesting to notice that
blaCTX−M−15 and blaCTX−M−1 have been found more frequently
in samples of the GI tract but also in wound and skin infection
isolates, where contamination of the wound due to the licking
in dogs is very common. Carriage of ESBL/pAmpC producing
E. coli of phylogroup B2, D, and F in the GI tract suggests
ExPEC intestinal carriage and a potential reservoir of multi-
drug resistant ExPEC producing bacteria in animal patients.
Previous studies have shown that colonization with E. coli of
phylogroup B2 in healthy individuals is commonly identified
in fecal E. coli in healthy humans and animals (Dale and
Woodford, 2015; Alonso et al., 2017) and our findings shows
that in diseased companion animals, fecal ExPEC isolates can
also be ESBL/pAmpC producers. Moreover, we have identified
ExPEC ESBL/pAmpC producers amongst clinical isolates from
all specimens including UTIs, body fluids/biopsies, skin, and
wound infections. This is an important finding for both patient
management and infection control in veterinary settings; ExPEC
are considered opportunistic colonizing pathogens (Price et al.,
2017) and intestinal carriage or skin/wound colonization in
immunocompromised patients can lead to infection. Equally
important, colonized patients can be a source for hospital
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dissemination of ExPEC ESBL/pAmpC producers as well as
posing a risk for interspecies transmission and a risk for owner
and family members. Therefore, infection control measures need
to be implemented upon detection of such bacteria to limit
their dissemination within veterinary premises, which needs
to be coupled by providing owners with information on the
significance of isolation of ESBL/pAmpC producers from their
pets and provide, for example, hand hygiene advice to reduce
transmission risks.
Accurate and rapid laboratory detection of ESBL/AmpC
phenotypes is critical for supporting management of patients
and infection control in hospitals and clinics. Whilst detection
of ESBL/pAmpC E. coli colonized patients will be always
useful for epidemiology and infection control, distinction
between colonization and true infection is critical for patient
therapeutic management and reducing unnecessary antibiotic
use. In our study, more ESCR isolates were obtained from
body sites populated with commensal flora where the role
played by the ESCR/ESBL/AmpC producing bacteria in the
infection is more difficult to establish as cultures generally
result in polymicrobial growth. Conversely, the vast majority
of ESCR isolates obtained from normally sterile sites were
obtained as pure cultures (77%). Urine samples collected
by cystocentesis (where the risk of contamination during
collection is the lowest) yielded pure cultures in 91% cases
and in most of these (61%) at least one criteria supportive
of infection was present. These findings suggest that obtaining
an ESCR E. coli isolate in pure culture, from a normally
sterile site is likely to be clinically significant and warrants
antimicrobial treatment. Whenever possible, cytology and Gram-
staining can be employed to aid decisions regarding the likely
infecting pathogen by revealing the phagocytozed organisms
with matching cellular morphology of those obtained from
bacterial cultures. Nevertheless, careful assessment of each case is
critical for appropriate antimicrobial selection as agents selected
to treat the infecting pathogen (other than an ESBL/AmpC
producer) may include β-lactam agents and which in turn
may select for ESBL/AmpC producers. Repeating bacterial
cultures following application of a stringent aseptic technique for
specimen collection can also help and should be recommended
to distinguish between contamination, transient colonization
and true infection.
Our study has shown that a variety of ESBL/pAmpC
producing E. coli isolates, including ExPEC, can be associated
with both colonization and infection in companion animals.
However, this work was performed on a bacterial population
originating from cases seen in the Small Animal and Equine
Referral Hospitals and may not be directly comparable to
the general companion animal population. Future prospective
studies are necessary to monitor the duration of ESBL/pAmpC
producing E. coli colonization and identify factors that may
trigger the transition from colonization to infection. Better
understanding and differentiation of ESBL/pAmpC producing
E. coli isolates obtained from clinical specimens as true
infecting agents or simply transient colonizers will reduce
antimicrobial use and therefore preserve the efficacy of currently
available antimicrobials and promote antimicrobial stewardship
in veterinary practice.
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